Compare Adaptive Biotechnologies Corp (ADPT) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while YieldMax TSLA Option Income Strategy ETF trades at $21.88. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | TSLY | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $25.45 | $48.25 |
52-Week Low | $12.30 | $20.49 |
Enterprise Value | $4.10B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
